Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cartesian Therapeutics, Inc. (RNAC : NSDQ)

• Company Description    Cartesian Therapeutics is a clinical-stage company pioneering RNA cell therapies for the treatment of autoimmune diseases. The company's lead asset, Descartes-08, is a potential first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy in Phase 2b clinical development for patients with generalized myasthenia gravis. Cartesian Therapeutics, formerly known as Selecta Biosciences Inc., is based in WATERTOWN, Mass. Number of Employees: 66

• Price / Volume Information    Yesterday's Closing Price: $7.21 Daily Weekly Monthly 20 Day Moving Average: 224,558 shares Shares Outstanding: 26.00 (millions) Market Capitalization: $187.49 (millions) Beta: 0.38 52 Week High: $20.12 52 Week Low: $5.98 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.49% 4.67% 12 Week -28.61% -29.76% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7495 New Horizon Way - Frederick,MD 21703 USA ph: 301-348-8698 fax: 617-924-3454 megan.leduc@cartesiantx.com http://www.cartesiantherapeutics.com

• General Corporate Information    Officers Carsten Brunn - President and Chief Executive Officer; and Directo Blaine Davis - Chief Financial Officer Carrie S. Cox - Director Timothy C. Barabe - Director Nishan de Silva - Director Peer Information Cartesian Therapeutics, Inc. (CORR.) Cartesian Therapeutics, Inc. (RSPI) Cartesian Therapeutics, Inc. (CGXP) Cartesian Therapeutics, Inc. (BGEN) Cartesian Therapeutics, Inc. (GTBP) Cartesian Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 816212302 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/12/26 Share - Related Items Shares Outstanding: 26.00 Most Recent Split Date: 4.00 (0.03:1) Beta: 0.38 Market Capitalization: $187.49 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.87 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.33 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -100.00% vs. Previous Quarter: -376.00% Sales Growth vs. Year Ago Period: 16.80% vs. Previous Quarter: 51.68% ROE 12/31/25 - - 09/30/25 - - 06/30/25 - - ROA 12/31/25 - - 09/30/25 - -11.95 06/30/25 - -6.36 Current Ratio 12/31/25 - - 09/30/25 - 10.67 06/30/25 - 13.33 Quick Ratio 12/31/25 - - 09/30/25 - 10.67 06/30/25 - 13.33 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - -4,371.41 06/30/25 - -3,506.15 Book Value 12/31/25 - - 09/30/25 - -1.38 06/30/25 - -0.10 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - -

Powered by Zacks Investment Research ©